HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Management of phosphate in chronic kidney disease--Clinical trials of lanthanum carbonate].

Abstract
The lanthanum carbonate which is the new phosphate binder decreased serum phosphorus value significantly in comparison with the placebo group, showed equal serum phosphorus decrease action to those at the capacity which in addition is less than calcium carbonate and sevelamer hydrochloride.
AuthorsKoichi Tatsuta, Takashi Shigematsu
JournalClinical calcium (Clin Calcium) Vol. 19 Issue 2 Pg. 219-23 (Feb 2009) ISSN: 0917-5857 [Print] Japan
PMID19182362 (Publication Type: Journal Article, Review)
Chemical References
  • lanthanum carbonate
  • Lanthanum
Topics
  • Chronic Disease
  • Humans
  • Hyperphosphatemia (drug therapy, etiology)
  • Kidney Diseases (complications)
  • Lanthanum (administration & dosage, therapeutic use)
  • Randomized Controlled Trials as Topic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: